Former Little Mix singer Jesy Nelson has expressed profound pride following a significant announcement from the National Health Service regarding newborn screening protocols. The NHS has confirmed that screenings for spinal muscular atrophy (SMA) will commence earlier than initially scheduled, marking what Nelson describes as a "major milestone" for affected families.
Campaign Inspired by Personal Experience
The 34-year-old artist has been a vocal advocate for universal SMA screening after her own twins, Ocean Jade and Story Monroe Nelson, were diagnosed with this rare degenerative condition. Spinal muscular atrophy leads to progressive muscle wastage and can have devastating consequences if not detected early.
Nelson's advocacy included a personal meeting with Health Secretary Wes Streeting earlier this year, where she detailed the life-changing impact that earlier detection could have had on her daughters' prognosis. She subsequently launched a petition calling for SMA to be included in the standard newborn blood spot screening test, commonly known as the heel-prick test.
Official Confirmation and Timeline Acceleration
In a formal letter addressed to Nelson and Giles Lomax, chief executive of the charity SMA UK, Health Secretary Wes Streeting confirmed that SMA screening evaluations will now begin in October 2026 rather than January 2027 as originally planned. The screening will be implemented through in-screening evaluations (ISE), which are used to test proposed new screening programmes before national adoption.
"My officials are still working through the challenges related to extending the ISE to the whole of England and I will keep you both updated of progress in this area," Streeting stated in his correspondence. "As you know, I'd like to see a full rollout. Scottish officials are working with the UK NSC to ensure that findings from this pilot can be shared, too."
Medical Significance and Treatment Options
Spinal muscular atrophy is a genetic disorder that affects motor neurons, leading to muscle weakness and wasting. Early intervention is crucial, as timely treatment can prevent some of the most severe manifestations of the condition. Nelson revealed in January that her daughters' diagnosis means they are unlikely to ever walk or regain neck strength.
The twins have since received a one-time gene therapy infusion designed to replace the missing gene responsible for SMA progression. While this treatment can halt further muscle deterioration, it cannot restore muscles that have already been lost.
Charity Response and Future Goals
Giles Lomax of SMA UK welcomed the announcement, stating: "Following years of campaigning we are delighted to see the formal announcement that screening for SMA will start in six months' time in England. This milestone will change the lives of so many diagnosed through the heel prick test."
He emphasized the organization's commitment to ensuring equitable access: "We will continue to work hard to ensure this SMA is rolled out to other parts of England as well as the home nations. No baby should be left behind based on where they live."
Nelson, who recently became a patron of SMA UK, shared the news on her Instagram story, describing it as a "big step forward" for the SMA community. "ISE have announced to start screening for SMA in England will now begin in October 2026," she wrote. "I am so proud, as this is a major milestone for the SMA Community."
The UK National Screening Committee's government website explains that in-screening evaluations serve as a crucial testing phase for proposed new screening programmes or modifications to existing ones before nationwide implementation. This accelerated timeline represents a significant victory for patient advocacy and demonstrates how personal experience can drive meaningful policy change within the healthcare system.
